

CYTODYN INC  
Form 8-K  
July 01, 2011

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): July 1, 2011

**CytoDyn Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Colorado**  
(State of Incorporation)

**000-49908**  
(Commission File Number)  
110 Crenshaw Lake Road, Lutz, Florida 33548

**75-3056237**  
(I.R.S. Employer Identification Number)

Edgar Filing: CYTODYN INC - Form 8-K

(Address of principal executive offices) (Zip code)

**Registrant's telephone number, including area code: (813) 527-6969**

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On July 1, 2011, CytoDyn Inc. (the Company) announced that its new corporate website is available at <http://www.cytodyn.com>. This site will allow viewers to obtain information regarding the Company as it continues to develop and evolve its science and business. We feel the new website represents the Company as it looks to the future, commented Kenneth J. Van Ness, President and Chief Executive Officer.

**Forward Looking Statements**

The statements in this Form 8-K constitute forward-looking statements and constitute forward-looking information within the meaning of United States securities laws. These statements and this information represent the Company's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond the Company's control. These factors could cause actual results to differ materially from such forward-looking statements or forward-looking information. The words believe, estimate, expect, intend, anticipate, foresee, plan, and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or on this forward-looking information.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CytoDyn Inc.

July 1, 2011

By: /s/ Kenneth J. Van Ness  
Kenneth J. Van Ness

President and CEO